A new manufacturing facility is being set up in Umeå by Diamyd Medical. The first priority of the new site is to receive the process technology for the manufacture of recombinant GAD65, the

STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Diamyd Medical investerar 1,2 miljoner kronor i Mainly AI, vilket ger en ägarandel på 20 procent i bolaget

Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production. Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency VINNOVA for a project that will design, test and build a sustainability framework powered by artificial intelligence (AI) for Diamyd Medical’s production facility in Umeå, Sweden. Diamyd Medical AB: Diamyd Medical makes an investment in MainlyAI As announced in December 2020, Diamyd Medical and MainlyAI are, together with the Royal Institute of Technology (KTH), engaged in a VINNOVA funded project to design, test and build a sustainability framework powered by artificial intelligence for Diamyd Medical’s production facility in Umeå, Sweden. Diamyd Medical’s investment will give a 20% ownership and a board seat in MainlyAI. The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector.

Diamyd medical makes an investment in mainly

The investment of SEK 1.2 million will facilitate MainlyAI's strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. As announced in December 2020, Diamyd Medical and MainlyAI are, together with the Royal Institute of Technology (KTH), engaged in a VINNOVA funded "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) Published Mar 05, 2021 "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) Diamyd Medical makes an investment in MainlyAI 1/20/2021 Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden +46 8 661 00 26 +46 8 661 63 68. Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency VINNOVA for a project that will design, test Diamyd Medical invests in MainlyA. Diamyd Medical’s investment will give a 20% ownership and a board seat in MainlyAI.

The investment will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where a first project is sustainable production within the pharmaceutical sector.

Ulf Hannelius, CEO of Diamyd Medical will, following the investment, join MainlyAI's Board of Directors. About MainlyAI MainlyAI is a research

Genmab. 1999.

Diamyd medical makes an investment in mainly

Ägare, Kapital.%, Röster.%. Anders Essen-Möller, 12,90%, 34,60%. Avanza Pension, 13,40%, 10,00%. Bertil Lindkvist, 9,00%, 6,80%. Nordnet

How has Diamyd Medical's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : DMYD B is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 9% a week. Diamyd Medical is in a very exciting phase of development right now, the company has provided strong clinical data verifying the potential of the treatment targeting an identified genetic HLA group of individuals with type 1 diabetes, and is planning for the clinical phase III trial. Photo of Maja Johansson.

n.a.. Diamyd.
Lediga jobb sodersjukhuset

The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. Diamyd Medical makes an investment in MainlyAI Mon, Feb 22, 2021 08:45 CET The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. Diamyd Medical makes an investment in MainlyAI (Cision) 2021-02-22 08:45 The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) Published Mar 05, 2021 "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) KTH and sustainability in other media. Page responsible: sustainability@kth.se.

Diamyd Medical's investment will give a 20% ownership and a board seat in MainlyAI. The investment of SEK 1.2 million will facilitate MainlyAI's strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. As announced in December 2020, Diamyd Medical and MainlyAI are, together with the Royal Institute of Technology (KTH), engaged in a VINNOVA funded "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) Published Mar 05, 2021 "Diamyd Medical makes an investment in MainlyAI" (news.cision.com) Diamyd Medical makes an investment in MainlyAI 1/20/2021 Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden +46 8 661 00 26 +46 8 661 63 68. Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency VINNOVA for a project that will design, test Diamyd Medical invests in MainlyA.
Billigaste fasta telefonabonnemang

berakna substansmangd
uu personalvetare
försörjningsstöd enköping öppettider
tv tablå 70 talet
fria bönder medeltiden
mat welsh
ib skolan helsingborg

Company profile page for DIAMYD MEDICAL AB including stock price, company news, press releases, executives, board members, and contact information

The investment of SEK 1.2 million will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where the first project is sustainable production within the pharmaceutical sector. STOCKHOLM, Dec. 3, 2020 /PRNewswire/ -- Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency Diamyd Medical invests in MainlyA. Diamyd Medical’s investment will give a 20% ownership and a board seat in MainlyAI. The investment will facilitate MainlyAI’s strategic focus on applying artificial intelligence, where a first project is sustainable production within the pharmaceutical sector. As announced in December 2020, Diamyd Medical and MainlyAI are, together with the Royal Institute of Technology (KTH), engaged Continue reading.